Boynton AL - Search Results

1

Comparison of serum PSMA, PSA levels with results of Cytogen-356 ProstaScint scanning in prostatic cancer patients.

Murphy GP, Maguire RT, Rogers B, Partin AW, Nelp WB, Troychak MJ, Ragde H, Kenny GM, Barren RJ 3rd, Bowes VA, Gregorakis AK, Holmes EH, Boynton AL. Murphy GP, et al. Among authors: boynton al. Prostate. 1997 Dec 1;33(4):281-5. doi: 10.1002/(sici)1097-0045(19971201)33:4<281::aid-pros9>3.0.co;2-k. Prostate. 1997. PMID: 9397201

2

Comparison of prostate specific membrane antigen, and prostate specific antigen levels in prostatic cancer patients.

Murphy G, Ragde H, Kenny G, Barren R 3rd, Erickson S, Tjoa B, Boynton A, Holmes E, Gilbaugh J, Douglas T. Murphy G, et al. Anticancer Res. 1995 Jul-Aug;15(4):1473-9. Anticancer Res. 1995. PMID: 7544569

3

In vitro propagated dendritic cells from prostate cancer patients as a component of prostate cancer immunotherapy.

Tjoa B, Erickson S, Barren R 3rd, Ragde H, Kenny G, Boynton A, Murphy G. Tjoa B, et al. Prostate. 1995 Aug;27(2):63-9. doi: 10.1002/pros.2990270202. Prostate. 1995. PMID: 7638084

4

Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity.

Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Tjoa B, et al. Prostate. 1996 Jan;28(1):65-9. doi: 10.1002/(SICI)1097-0045(199601)28:1<65::AID-PROS9>3.0.CO;2-N. Prostate. 1996. PMID: 8545283

5

Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A0201-specific peptides from prostate-specific membrane antigen.

Murphy G, Tjoa B, Ragde H, Kenny G, Boynton A. Murphy G, et al. Prostate. 1996 Dec;29(6):371-80. doi: 10.1002/(SICI)1097-0045(199612)29:6<371::AID-PROS5>3.0.CO;2-B. Prostate. 1996. PMID: 8977634 Clinical Trial.

6

Dendritic cell-based immunotherapy of prostate cancer.

Salgaller ML, Tjoa BA, Lodge PA, Ragde H, Kenny G, Boynton A, Murphy GP. Salgaller ML, et al. Crit Rev Immunol. 1998;18(1-2):109-19. doi: 10.1615/critrevimmunol.v18.i1-2.120. Crit Rev Immunol. 1998. PMID: 9419453 Clinical Trial.

7

Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment.

Murphy GP, Tjoa BA, Simmons SJ, Ragde H, Rogers M, Elgamal A, Kenny GM, Troychak MJ, Salgaller ML, Boynton AL. Murphy GP, et al. Among authors: boynton al. Prostate. 1999 Apr 1;39(1):54-9. doi: 10.1002/(sici)1097-0045(19990401)39:1<54::aid-pros9>3.0.co;2-u. Prostate. 1999. PMID: 10221267 Clinical Trial.

8

GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial.

Simmons SJ, Tjoa BA, Rogers M, Elgamal A, Kenny GM, Ragde H, Troychak MJ, Boynton AL, Murphy GP. Simmons SJ, et al. Among authors: boynton al. Prostate. 1999 Jun 1;39(4):291-7. doi: 10.1002/(sici)1097-0045(19990601)39:4<291::aid-pros10>3.0.co;2-9. Prostate. 1999. PMID: 10344219 Clinical Trial.

9

Follow-up evaluation of a phase II prostate cancer vaccine trial.

Tjoa BA, Simmons SJ, Elgamal A, Rogers M, Ragde H, Kenny GM, Troychak MJ, Boynton AL, Murphy GP. Tjoa BA, et al. Among authors: boynton al. Prostate. 1999 Jul 1;40(2):125-9. doi: 10.1002/(sici)1097-0045(19990701)40:2<125::aid-pros8>3.0.co;2-y. Prostate. 1999. PMID: 10386473 Clinical Trial.

10

Comparison of prostate specific antigen, prostate specific membrane antigen, and LNCaP-based enzyme-linked immunosorbent assays in prostatic cancer patients and patients with benign prostatic enlargement.

Murphy GP, Holmes EH, Boynton AL, Kenny GM, Ostenson RC, Erickson SJ, Barren RJ. Murphy GP, et al. Among authors: boynton al. Prostate. 1995 Mar;26(3):164-8. doi: 10.1002/pros.2990260308. Prostate. 1995. PMID: 7534919

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

134 results

Search Page

Filters